Cart
sales@molnova.com
SPOP-IN-6lc
CAS No. 2136270-56-7
SPOP-IN-6lc( —— )
Catalog No. M36313 CAS No. 2136270-56-7
SPOP-IN-6lc is a potent SPOP inhibitor with multiple roles in cancer, oncostatic in a variety of tumors, but functions as an oncogene in renal cancer.SPOP-IN-6lc can be used to study cell signaling and apoptosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 233 | In Stock |
|
| 5MG | 366 | In Stock |
|
| 10MG | 587 | In Stock |
|
| 25MG | 1067 | In Stock |
|
| 50MG | 1435 | In Stock |
|
| 100MG | 1881 | In Stock |
|
| 500MG | 3807 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSPOP-IN-6lc
-
NoteResearch use only, not for human use.
-
Brief DescriptionSPOP-IN-6lc is a potent SPOP inhibitor with multiple roles in cancer, oncostatic in a variety of tumors, but functions as an oncogene in renal cancer.SPOP-IN-6lc can be used to study cell signaling and apoptosis.
-
DescriptionSPOP-IN-1 is a selective SPOP E3 ubiquitin ligase inhibitor. SPOP-IN-1 leads to the accumulation of tumor suppressors PTEN and DUSP7 and decreased levels of phosphorylated AKT and ERK in clear-cell renal cell carcinoma.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2136270-56-7
-
Formula Weight505.64
-
Molecular FormulaC26H31N7O2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(CC1=CC=CS1)N2C3=C(C(=O)N4C(=N3)C(C)=CC=C4)C=C(C(NCCN5CCN(C)CC5)=O)C2=N
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Dong Z, et al. Structure-Activity Relationship of SPOP Inhibitors against Kidney Cancer. J Med Chem. 2020 May 14;63(9):4849-4866. ?
molnova catalog
related products
-
Isatuximab
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38 in malignant cells of the hematological system, a highly expressed protein in multiple myeloma.
-
CDK8-IN-13
CDK8-IN-13 is a CDK8 inhibitor (IC50: 51.9 nM) with potent, selective and oral activity. CDK8-IN-13 induces apoptosis and reduces the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 exhibits anti-tumour activity.
-
FC-116
FC-116 is a potent Tubulin inhibitor with antitumour activity and inhibits tumour growth in mice.
